Stimulant Oxytocin Study (SOS)
Stimulant Use & Co-occuring Opioid Use Disorders
About this trial
This is an interventional treatment trial for Stimulant Use & Co-occuring Opioid Use Disorders focused on measuring oxytocin, substance-related disorders, Opioid Replacement Therapy, Psychophysiology, Stress Biomarkers
Eligibility Criteria
Inclusion Criteria:
- At least 18 years old
- Enrolled as a patient who at the SFVAMC Opioid Treatment Program or the Oakland Behavioral Health Clinic Opioid Treatment Program
- Stable dose of opioid replacement therapy for at least 2 consecutive weeks
- Veteran
- One documented urine toxicology screen positive for stimulants in the past 12 months.
Exclusion Criteria:
- Severe neuropsychological disorder
- Suicidal or homicidal ideation within the past 90 days or a suicide attempt in the past 6 months
- Hemodialysis, unless participant can produce urine samples weekly
- Sensitivity to methylparaben or propylparaben
- Positive urine pregnancy test or women of childbearing age not practicing effective means of non-hormonal birth control
- Chronic nasal obstruction, discharge, or bleeding
Sites / Locations
- VA Northern California Health Care System, Mather, CA
- San Francisco VA Medical Center, San Francisco, CA
- VA Portland Health Care System, Portland, OR
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Oxytocin
Placebo
Patients in methadone maintenance treatment (MMT) programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring opioid use disorder (OUD) to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.
Patients in MMT programs are required to come in every day for their methadone. Additionally they are required to come in weekly for psycho- educational/therapy groups, biweekly random urine screenings, and monthly individual therapy sessions. The investigators will piggy-back off this existing structure and randomize Veterans with stimulant use disorders and receiving MMT for co-occurring OUD to receive either oxytocin or placebo, to be administered twice daily for six weeks while in the MMT program.